Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination

We reported a patient with neutrophilic urticaria following COVID‐19 vaccination who required high‐dose steroid treatment.[Image: see text]

Detalles Bibliográficos
Autores principales: Matsubara, Akihiro, Sakurai, Mai, Morita, Akimichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Correspondences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427069/
http://dx.doi.org/10.1002/cia2.12199
_version_ 1783750123826708480
author Matsubara, Akihiro
Sakurai, Mai
Morita, Akimichi
author_facet Matsubara, Akihiro
Sakurai, Mai
Morita, Akimichi
author_sort Matsubara, Akihiro
collection PubMed
description We reported a patient with neutrophilic urticaria following COVID‐19 vaccination who required high‐dose steroid treatment.[Image: see text]
format Online
Article
Text
id pubmed-8427069
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84270692021-09-09 Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination Matsubara, Akihiro Sakurai, Mai Morita, Akimichi Journal of Cutaneous Immunology and Allergy Correspondences We reported a patient with neutrophilic urticaria following COVID‐19 vaccination who required high‐dose steroid treatment.[Image: see text] John Wiley and Sons Inc. 2021-08-18 /pmc/articles/PMC8427069/ http://dx.doi.org/10.1002/cia2.12199 Text en © 2021 The Authors. Journal of Cutaneous Immunology and Allergy published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society for Cutaneous Immunology and Allergy. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Correspondences
Matsubara, Akihiro
Sakurai, Mai
Morita, Akimichi
Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
title Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
title_full Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
title_fullStr Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
title_full_unstemmed Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
title_short Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
title_sort neutrophilic urticarial dermatosis following bnt162b2 (pfizer–biontech) covid‐19 vaccination
topic Correspondences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427069/
http://dx.doi.org/10.1002/cia2.12199
work_keys_str_mv AT matsubaraakihiro neutrophilicurticarialdermatosisfollowingbnt162b2pfizerbiontechcovid19vaccination
AT sakuraimai neutrophilicurticarialdermatosisfollowingbnt162b2pfizerbiontechcovid19vaccination
AT moritaakimichi neutrophilicurticarialdermatosisfollowingbnt162b2pfizerbiontechcovid19vaccination

Ejemplares similares